This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.
Fully understand the study and voluntarily sign the informed consent form.
Female 18-75 years of age;
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Histologically or cytologically confirmed advanced cervical cancer, including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.
Patients were deemed unsuitable for participating in the study by the investigator for any reasons.